Open AccessShort and long‐term safety of MP29‐02*: a new therapy for the treatment of allergic rhinitis
Author(s) -
Price David,
Bousquet Jean,
Hellings Peter,
Scadding Glenis,
Fokkens Wytske,
Munzel Ullrich,
Bachert Claus
Publication year - 2013
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-3-s2-o15
Subject(s) - medicine , fluticasone propionate , nostril , adverse effect , dysgeusia , placebo , randomized controlled trial , nasal congestion , pediatrics , anesthesia , surgery , nose , asthma , alternative medicine , pathology
Method 4022 patients (>=12 years old) were randomized into 4, 14-day double-blind, placebo-controlled SAR trials to receive MP29-02*, AZE, FP or placebo nasal sprays (all given as 1 spray/nostril bid). 612 patients (>=12 years old) were randomized into a 1-year, open-label, active-controlled, parallel-group chronic rhinitis trial to receive MP29-02* (1 spray/nostril bid) or FP nasal spray (2 sprays/nostril qd). For all studies the total daily dose of AZE and FP was 548 g and 200 μg respectively. Safety was assessed by incidence, type, and severity of adverse events, vital signs and nasal examination.